Author

Miguel Regueiro

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Best of IBD
Best of IBD

Miguel Regueiro

Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)
Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)

Miguel Regueiro  et al.

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Miguel Regueiro  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Miguel Regueiro  et al.

HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Miguel Regueiro  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Miguel Regueiro  et al.

IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT
IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT

Miguel Regueiro  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Miguel Regueiro  et al.

EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Miguel Regueiro  et al.

BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS
BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS

Miguel Regueiro  et al.

TOFACITINIB IN ULCERATIVE COLITIS: THE RELATIONSHIP BETWEEN OCTAVE INDUCTION WEEK 8 SYMPTOMATIC REMISSION AND OCTAVE SUSTAIN WEEK 52 REMISSION
TOFACITINIB IN ULCERATIVE COLITIS: THE RELATIONSHIP BETWEEN OCTAVE INDUCTION WEEK 8 SYMPTOMATIC REMISSION AND OCTAVE SUSTAIN WEEK 52 REMISSION

Miguel Regueiro  et al.

RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Miguel Regueiro  et al.

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

Miguel Regueiro  et al.

Item 1 - 14 / 14
1